Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Century Therapeutics Inc(IPSC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IPSC
10/26/2026: IPSC (3-star) is currently NOT-A-BUY. Pass it for now.
Century Therapeutics is an early-stage biotechnology company developing allogeneic iPSC-derived cell therapies aimed at transforming the treatment of autoimmune diseases and cancer. The company's primary strength lies in its proprietary Allo-Evasion™ technology, which potentially allows for safer, off-the-shelf therapies. Its growth story hinges on the success of the CNTY-813 program for type 1 diabetes, which is moving toward clinical trials. Primary risks include the inherent uncertainty of clinical development, intense competition from well-funded rivals, and long-term funding needs. This stock is best suited for high-risk, long-term growth investors who should monitor upcoming IND submissions and clinical data readouts to gauge progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential through innovative platform technology but lacks commercial products to sustain long-term growth. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may favor the stock during periods of positive clinical news or regulatory updates, conditional on a strong upturn signal. |
| Value investor | Weak fit | The lack of earnings and early-stage status makes this an unsuitable candidate for traditional value-based valuation metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and is in an early-stage cash-consumption phase. |
| Low-risk investor | Weak fit | The speculative nature and clinical development risk make the stock unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a pre-commercial biotech, the stock is highly sensitive to news, clinical data, and sentiment. |
| Valuation risk | High | Valuations are based on future potential rather than current fundamentals, leaving the stock vulnerable to broad market corrections. |
| Competition risk (Allogeneic cell therapy) | High | The market is crowded with well-funded competitors like CRISPR and Allogene racing for similar clinical milestones. |
| Business quality | Medium | The company has a solid technical foundation, but lacks the commercial maturity of established pharmaceutical players. |
| Dividend income | Low / none | There is no income generation for investors at this stage of the company's life cycle. |
| Execution risk | High | Failure to achieve upcoming clinical IND or efficacy milestones would materially impair the investment thesis. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 171.31% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 264.37M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 844.9K shares | Beta 1.67 | 52 Weeks Range 0.43 - 3.04 | Updated Date 10/25/2026 |
52 Weeks Range 0.43 - 3.04 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Currently focuses on developing and testing iPSC-derived cell therapies; no recurring commercial revenue. | The company spends money on research and clinical trials, aiming to license or eventually sell successful medical therapies. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -61.37M | Price to Sales(TTM) 3.72 |
Enterprise Value -61.37M | Price to Sales(TTM) 3.72 | ||
Enterprise Value to Revenue 3.13 | Enterprise Value to EBITDA 131.51 | Shares Outstanding 181.08M | Shares Floating 101.25M |
Shares Outstanding 181.08M | Shares Floating 101.25M | ||
Percent Insiders 8.14 | Percent Institutions 87.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.